...
首页> 外文期刊>International Journal of Pharmacy and Pharmaceutical Sciences >SYNERGISTIC GROWTH INHIBITORY EFFECT OF FLAVONOL–KAEMPFEROL AND CONVENTIONAL CHEMOTHERAPEUTIC DRUGS ON CANCER CELLS
【24h】

SYNERGISTIC GROWTH INHIBITORY EFFECT OF FLAVONOL–KAEMPFEROL AND CONVENTIONAL CHEMOTHERAPEUTIC DRUGS ON CANCER CELLS

机译:黄酮-萘酚和常规化疗药物对癌细胞的协同生长抑制作用。

获取原文
           

摘要

Objective: The objective of the present study was to evaluate synergistic growth inhibitory effect of a flavonol, kaempferol in combination with chemotherapeutic drugs doxorubicin or cisplatin. Methods: The anti-proliferative activities of kaempferol, doxorubicin and cisplatin on human colorectal cancer cells (HCT-15) and human breast cancer (MDA MB 231) were analyzed by 3-(4,5-dimehylthiaol-2-yl)-2,5-diphenyltetraolium bromide (MTT) assay. Further, combinational studies were performed in both the cell lines to evaluate the interaction of drugs with kaempferol. The combination index (CI) method was used to assess the synergism of kaempferol with doxorubicin or cisplatin. Finally, morphological alterations associated with apoptosis were examined under fluorescent microscope. Results: All compounds showed dose-dependent growth inhibition in both HCT-15 and MDA MB 231 cells. The phytochemical kaempferol showed fifty percent inhibitory concentrations (IC 50 ) at 120±3.2 μg/ml and 64±1.2 μg/ml on HCT-15 and MDA MB 231 respectively. IC 50 concentrations of doxorubicin and cisplatin on both the cell lines were achieved at 49.6±0.5 μg/ml, 25.4±2.9 μg/ml and 44±1.8 μg/ml, 40.6±0.8 μg/ml respectively. Further, in vitro therapeutic effect (IC 50 ) of doxorubicin and cisplatin in terms of cell growth inhibition on HCT-15 cells were achieved at their one-fifth (10±0.83 μg/ml) and half (10±1.34 μg/ml) concentrations respectively when they were combined with 30 μg/ml of kaempferol individually. Simultaneously, on MDA-MB 231 cell line, the IC 50 concentrations were reduced to 18±1.22 μg/ml and 15±1.87 μg/ml respectively in combination with 32 μg/ml of kaempferol. The combinational index studies revealed the synergistic association of kaempferol with doxorubicin and cisplatin individually in each cell line. The fluorescence imaging studies strongly supported the synergistic association between kaempferol and doxorubicin or cisplatin by confirming significant apoptotic cell death in both the cell lines which was ~3 fold higher than each agent alone. Conclusion: The study reveals the prominent synergism between the phytochemical, kaempferol and chemotherapeutic drugs doxorubicin or cisplatin which helps in elevating the therapeutic efficacy of drugs.
机译:目的:本研究的目的是评估黄酮醇,山emp酚与化疗药物阿霉素或顺铂联合的协同生长抑制作用。方法:用3-(4,5-二甲硫基噻唑-2-基)-2分析山,酚,阿霉素和顺铂对人大肠癌细胞(HCT-15)和人乳腺癌(MDA MB 231)的抗增殖活性。 ,5-二苯基四溴化溴化物(MTT)分析。此外,在两种细胞系中进行了组合研究,以评估药物与山ka酚的相互作用。联合指数(CI)方法用于评估山奈酚与阿霉素或顺铂的协同作用。最后,在荧光显微镜下检查与凋亡相关的形态学改变。结果:所有化合物在HCT-15和MDA MB 231细胞中均表现出剂量依赖性的生长抑制作用。植物化学山emp酚对HCT-15和MDA MB 231的抑制浓度(IC 50)分别为120±3.2μg/ ml和64±1.2μg/ ml。两种细胞系中阿霉素和顺铂的IC 50浓度分别达到49.6±0.5μg/ ml,25.4±2.9μg/ ml和44±1.8μg/ ml,40.6±0.8μg/ ml。此外,就细胞对HCT-15细胞的生长抑制而言,阿霉素和顺铂的体外治疗效果(IC 50)达到其五分之一(10±0.83μg/ ml)和一半(10±1.34μg/ ml)。分别与30μg/ ml山奈酚合并使用时的最大浓度。同时,在MDA-MB 231细胞系中,与32μg/ ml的山emp酚组合,IC 50浓度分别降至18±1.22μg/ ml和15±1.87μg/ ml。组合指数研究表明,在每种细胞系中,山奈酚与阿霉素和顺铂分别协同协同作用。荧光成像研究通过证实两种细胞系中明显的凋亡细胞死亡,比单独的每种药物高约3倍,从而强烈支持山奈酚与阿霉素或顺铂之间的协同缔合。结论:该研究揭示了植物化学,山ka酚和化学治疗药物阿霉素或顺铂之间的显着协同作用,有助于提高药物的治疗效果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号